farction (STEMI) (1). Intra-aortic balloon pump (IABP)
is widely used for hemodynamic support in cardio- Data were obtained from the NIS, which contains discharge-level data from w8 million hospitalizations annually from w1,000 hospitals across the United States. All hospitalizations with the principal diagnosis of STEMI, identified using ICD-9-CM codes, were considered for inclusion. Of these patients, we included all patients with an additional diagnosis of cardiogenic shock (ICD-9: 785.51). The use of MCS was determined using ICD-9 procedure codes.
These included IABP (ICD-9: 37.61), Impella/Tandem Heart (ICD-9: 37.68), nonpercutaneous devices (ICD-9: 37.60, 37.62, 37.65), extracorporeal membrane and medium-sized hospitals (50.5%) compared with to reduce some of these discrepancies (7).
Our study has several limitations. First, NIS is an administrative database, which may be subject to errors in coding of diseases or procedures.
Cardiogenic shock was identified using the ICD-9 code reported by the treating hospital and thus may not be uniform across participating institutions. Unlike the IABP-SHOCK II trial, which included all acute myocardial infarction patients, our study was restricted to patients with STEMI. Identification of patients with non-STEMI in an administrative dataset Please note: Dr. Menon is a consultant for and has received a research grant from AstraZeneca; and is a consultant for Takeda Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
